No dose-dependent tubulotoxicity of 5-aminosalicylic acid: A prospective study in patients with inflammatory bowel diseases

International Journal of Colorectal Disease

Volumn 18, Issue 5, 2003, Pages 406-412

  Dehmer, Carsten ^a   Greinwald, Roland ^b   Löffler, Juergen ^c   Grotz, Wolfgang ^a   Wolf, Lothar ^d   Hagmann, Hans Burkhardt ^e   Schneider, Werner ^e   Kreisel, Wolfgang ^a   Koester, W ^a   Schoelmerich, J ^f   Andus, T ^f   Kramm, H J ^e   Staritz, M ^g   Schenk, J ^e   Wolf, G ^e   Brom, A ^h   Hommel, E ^e   Struckmeyer, C ^e   Gierend, M ^e   Plassmann, T ^e  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Dr Falk Pharma GmbH   (Germany)

^c Medicomp GmbH   (Germany)

^d Medizinische Klinik Schwenningen   (Germany)

^e University of Regensburg ^*

^f UNIVERSITY OF REGENSBURG   (Germany)

^g Clinical Center Villingen Schwenningen   (Germany)

^h Klinik Oberwald   (Germany)

Author keywords

N acetyl D glucosaminidase; 5 Aminosalicylic acid; Chronic inflammatory bowel disease; Renal tubular damage

Indexed keywords

ACETYLGLUCOSAMINIDASE; AMINOSALICYLIC ACID; AZATHIOPRINE; BIOCHEMICAL MARKER; CORTICOSTEROID; CYCLOSPORIN A; EUDRAGIT; HISTAMINE H2 RECEPTOR ANTAGONIST; LIVER ENZYME; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN; PROTON PUMP INHIBITOR; STEROID;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CHRONIC INFLAMMATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DATA ANALYSIS; DIARRHEA; DOSE RESPONSE; ENTERITIS; FEMALE; HUMAN; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY TUBULE DAMAGE; LIVER TOXICITY; MALE; MONITORING; MULTICENTER STUDY; OPEN STUDY; PANCREATITIS; PERICARDITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BETA-N-ACETYL-GALACTOSAMINIDASE; BIOLOGICAL MARKERS; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEXOSAMINIDASES; HUMANS; KIDNEY TUBULES; MALE; MESALAMINE; PROSPECTIVE STUDIES; RECEPTORS, INTERLEUKIN-2; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 10744232950     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-002-0467-7     Document Type: Article

References (42)

1. Sands BE (2000) Therapy of inflammatory bowel disease. Gastroenterology 118 [Suppl 1]:S68-S82
2. Hanauer SB, Sandborn W (2001) Management of Crohn's disease in adults. Am J Gastroenterol 96:635-643
3. Sandborn W (1998) Therapy for ulcerative colitis. Cur Opin Gastroenterol 14:312-316
4. Rutgeerts P (1998) Medical therapy of inflammatory bowel disease. Digestion 59:453-469
5. Singleton JW, Hanauer SB, Gitnick GL, et al (1993) Mesalamine capsules for the treatment of active Crohn's disease: results of a 16 week trial. Gastroenterology 104:1293-1301
6. Riley SA (1998) What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis? Gut 42:761-763
7. Prakash A, Markham A (1999) Oral delayed-release mesalazine. A review of its use in ulcerative colitis and Crohn's disease. Drugs 57:383-408
8. Gisbert JP, Gamollón F, Maté J, Pajares JM (2002) Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease. A systematic review. Dig Dis Sci 47:471-488
9. Marteau P, Nelet F, Le Lu M, Devaux C (1996) Adverse events in patients treated with 5-aminosalicylic acid: 1993-1994 pharmacovigilance report for Pentasa in France. Aliment Pharmacol Ther 10:949-956
10. Brimblecombe R (1990) Mesalazine: a global safety evaluation. Scand J Gastroenterol 172 [Suppl] 66
11. Calder IC, Funder CC, Green CR, et al (1972) Nephrotoxic lesions from 5-aminosalicylic acid. BMJ 1:52-54
12. Novis BH, Korzets Z, Chen P, Bernheim J (1988) Nephrotic syndrome after treatment with 5-aminosalicylic acid. BMJ 296:1442
13. Muehlendahl KE (1989) Nephritis durch 5-Aminosalicylsäure. Dtsch Med Wochenschr 114:236
14. Henning HV, Meinhold J, Eisenhauer T, et al (1989) Chronische interstitielle Nephritis nach Behandlung mit 5-Aminosalicylsäure. Dtsch Med Wochenschr 114:1091
15. Barbour VM, Williams PF (1990) Nephrotic syndrome associated with sulphasalazine. BMJ 301:818
16. Dwarakanath AD, Michael J, Allan RN (1992) Sulphasalazine induced renal failure. Gut 33:1006-1007
17. Thuluvath PJ, Ninkovic M, Calam J, Anderson M (1994) Mesalazine induced interstitial nephritis. Gut 35:1493-1496
18. Witte T, Olbricht CJ, Koch KM (1994) Interstitial nephritis associated with 5-aminosalicylic acid. Nephron 67:481-482
19. Fornaciari G, Maccari S, Borgatti PP, et al (1997) Nephrotic syndrome from 5-ASA for Ulcerative Colitis? J Clin Gastroenterol 24:37-39
20. Margetts PJ, Churchill DN, Alexopoulou I (2001) Interstitial nephritis in patients with inflammatory bowel disease treated with mesalamine. J Clin Gastroenterol 32:176-178
21. Diener U, Tuczek HV, Fischer C, et al (1984) Renal function was not impaired by treatment with 5-aminosalicylic acid in rats and man. Arch Pharmacol (Weinheim) 326:278-282
22. Roth M, Steinhauer HB, Gerok W, Schölmerich J (1991) Beta-2-microglobulin and prostaglandin E2 excretion is increased in patients with inflammatory bowel disease - a new extraintesinal manifestation? Gastroenterology 100:A245
23. Riley SA, Lloyd D, Mani V (1992) Tests in renal function in patients with quiescent colitis: effect of drug treatment. Gut 33:1348-1352
24. Kreisel W, Wolf LM, Grotz W, Grieshaber M (1996) Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease. Eur J Gastroenterol Hepatol 8:461-468
25. Mahmud N, McDonald GSA, Kelleher D, Weir DG (1996) Microalbuminuria correlates with intestinal histopathological grading in patients with inflammatory bowel disease. Gut 38:99-103
26. Schreiber S, Haemling J, Zehnter E, et al (1997) Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut 40:761-766
27. Birketvedt GS, Berg KJ, Fausa O, Florholmen J (2000) Glomerular and tubular renal functions after long-term medication of sulphasalazine, olsalazine, and mesalazine in patients with ulcerative colitis. Inflamm Bowel Dis 6:275-279
28. Herrlinger KR, Noftz MK, Fellermann K, et al (2001) Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use. Aliment Pharmacol Ther 15:363-369
29. Fraser JS, Muller AF, Smith DJ, et al (2001) Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy. Aliment Pharmacol Ther 15:1131-1137
30. Price RG (1992) The role of β-NAG in the diagnosis of kidney disease including the monitoring of nephrotoxicity. Clin Nephrol 38, Suppl 1: 14-19
31. Hadziselimovic F, Emmons LR, Gallati H (1995) Soluble tumor necrosis receptors p55 and p75 in the urine monitor disease activity and the efficacy of treatment in inflammatory bowel disease. Gut 37:260-263
32. Van Deventer SJH (1997) Tumor necrosis factor and Crohn's disease. Gut 40:443-448
33. Murch SH, Lamkin VA, Savage MO (1991) Serum concentrations of tumor necrosis factor-α in childhood chronic inflammatory bowel disease. Gut 32:913-917
34. Armstrong MA, Gardiner KR, Kirk SJ, Halliday MI, Rowlands BJ (1997) Tumor necrosis factor and inflammatory bowel disease. Br J Surg 84:1051-1058
35. Holtkamp W, Stollberg T, Reis HE (1995) Serum interleukin-6 is related to disease activity but not disease specificity in inflammatory bowel disease. J Clin Gastroenterol 20:123-126
36. Nielsen OH, Ciardelli T, Wu Z, et al (1995) Circulating soluble interleukin-2 receptor α and β chain in inflammatory bowel disease. Am J Gastroenterol 90:1301-1306
37. Jung K (1994) Urinary enzymes and low molecular weight proteins as markers of tubular dysfunctions. Kidney Int 46 [Suppl 47]:S29-S33
38. Scherberich JE (1989) Immunological and ultrastructural analysis of loss of tubular membrane-bound enzymes in patients with renal damage. Clin Chim Acta 185:271-282
39. Weber MH, Verwiebe R (1992) α1-Microglobulin (protein HC): features of a promising indicator of proximal tubular dysfunction. Eur J Clin Chem Clin Biochem 30:683-691
40. Berg KJ, Kristoffersen DT, Djøseland O, et al (1998) Reference range of some enzymes and proteins in untimed overnight urine and their stability after freezing. Clin Chim Acta 272:225-230
41. Altman DG (1991) Practical Statistics for Medical Research. Chapman & Hall
42. Mahmud N, O'Toole D, O'Hare N, Freyne PJ, Weir DG, Kelleher D (2002) Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. Aliment Pharmacol Ther 16:207-215